Beta Bionics, Inc. Common Stock (BBNX) - Total Assets
Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) holds total assets worth $304.42 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BBNX net asset quality score to measure how much of total assets are equity-financed.
Beta Bionics, Inc. Common Stock - Total Assets Trend (2022–2025)
This chart illustrates how Beta Bionics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Explore how much of Beta Bionics, Inc. Common Stock's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Beta Bionics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Beta Bionics, Inc. Common Stock's total assets of $304.42 Million consist of 81.5% current assets and 18.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.6% |
| Accounts Receivable | $19.89 Million | 6.1% |
| Inventory | $21.72 Million | 6.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Beta Bionics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Beta Bionics, Inc. Common Stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beta Bionics, Inc. Common Stock's current assets represent 81.5% of total assets in 2025, an increase from 80.1% in 2022.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2025, down from 77.9% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is inventory at 6.6% of total assets.
Beta Bionics, Inc. Common Stock Competitors by Total Assets
Key competitors of Beta Bionics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Beta Bionics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.69 | 15.88 | 9.77 |
| Quick Ratio | 9.67 | 14.93 | 9.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $224.79 Million | $245.42 Million | $93.02 Million |
Beta Bionics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Beta Bionics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.28 |
| Latest Market Cap to Assets Ratio | 1.79 |
| Asset Growth Rate (YoY) | 119.7% |
| Total Assets | $328.74 Million |
| Market Capitalization | $587.77 Million USD |
Valuation Analysis
Above Book Valuation: The market values Beta Bionics, Inc. Common Stock's assets above their book value (1.79x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Beta Bionics, Inc. Common Stock's assets grew by 119.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Beta Bionics, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of Beta Bionics, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $328.74 Million | +119.68% |
| 2024-12-31 | $149.65 Million | +35.99% |
| 2023-12-31 | $110.04 Million | +209.74% |
| 2022-12-31 | $35.53 Million | -- |
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Pa… Read more